Algeta ASA: Net Sales of Xofigo for Third Quarter 2013 Not intended for US media Oslo, Norway, 31 October 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that Bayer, in its third quarter 2013 results presented today, disclosed that US net sales for Xofigo (radium Ra 223 dichloride) during the period amounted to EUR12m (USD17m). As previously announced, Algeta will report third quarter 2013 results on Wednesday, 6 November 2013. A presentation by members of Algeta's executive management team to investors, analysts and the press will take place in Oslo at 10:00 CET. Algeta will also host an international conference call at 14:30 CET/08:30 Eastern Time. About Radium Ra 223 Dichloride Radium Ra 223 dichloride (radium-223) is currently not approved by the European Medicines Agency (EMA) or other authorities outside the US. Bayer submitted a Marketing Authorisation Application to the EMA for radium-223 in December 2012 and subsequently in other territories. Radium-223 (as Xofigo^® injection) is approved in the United States and is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Radium Ra 223 dichloride (radium-223) is an alpha particle-emitting pharmaceutical. Its active moiety mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent tumour cells, resulting in a potent cytotoxic effect. Additional effects on the tumour microenvironment including osteoblasts and osteoclasts also contribute to the in vivo efficacy. The alpha particle range from radium-223 is less than 100 micrometers (less than 10 cell diameters) which minimises damage to the surrounding normal tissue. In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of radium-223. Under the terms of the agreement, Bayer will develop, apply for health authority approvals worldwide and commercialize Xofigo globally. Algeta is eligible for royalties and milestones based on Bayer's sales of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer in the US. ### Xofigo^® is a registered trademark of Bayer AG For further information, please contact: Mike Booth +1 646 410 1884 Communications & Corporate Affairs firstname.lastname@example.org Media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson email@example.com Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton firstname.lastname@example.org Investor enquiries: Tricia Truehart +1 646 378 2953 The Trout Group email@example.com About Algeta Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Press release ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Algeta ASA via Thomson Reuters ONE HUG#1739450
Algeta ASA: Net Sales of Xofigo for Third Quarter 2013
Press spacebar to pause and continue. Press esc to stop.